EICHOR
● Active Not Recruiting
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Condition: Hepatocellular Carcinoma · Liver Cancer · Sponsor: Bristol-Myers Squibb
About this study
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (184)
| Local Institution - 0081 | Anniston, Alabama, United States | — |
| Mayo Clinic in Arizona - Phoenix | Phoenix, Arizona, United States | — |
| Arizona Oncology Associates, PC - HOPE | Tucson, Arizona, United States | — |
| Local Institution - 0135 | Los Angeles, California, United States | — |
| Local Institution - 0088 | Palo Alto, California, United States | — |
| Local Institution - 0085 | San Francisco, California, United States | — |
| Local Institution - 0235 | Aurora, Colorado, United States | — |
| Local Institution - 0267 | Miami, Florida, United States | — |
| Sylvester Comprehensive Cancer Center/ UMHC | Miami, Florida, United States | — |
| Local Institution - 0163 | Tampa, Florida, United States | — |
| Local Institution - 0009 | Atlanta, Georgia, United States | — |
| Local Institution - 0025 | Westwood, Kansas, United States | — |
+ 172 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03383458